Nerlynx and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Nerlynx (neratinib maleate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Imodium, and have Breast cancer.

The phase IV clinical study analyzes which people have Weakness when taking Nerlynx. It is created by eHealthMe based on reports of 1,945 people who have side effects when taking Nerlynx from the FDA, and is updated regularly.

What is Nerlynx?

Nerlynx has active ingredients of neratinib maleate. eHealthMe is studying from 1,946 Nerlynx users. Check the latest studies of Nerlynx.

What is Weakness?

Weakness is found to be associated with 3,641 drugs and 6,611 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 10, 2026

1,945 people reported to have side effects when taking Nerlynx.
Among them, 100 people (5.14%) have Weakness.

Among these 100 people:

How long have people been on Nerlynx when they have Weakness? *

What is the gender of people who have Weakness when taking Nerlynx? *

female: 100 %
male: 0.0 %

What is the age of people who have Weakness when taking Nerlynx? *

What are other drugs people take besides Nerlynx? *

What are other side effects people have besides Weakness? *

Diarrhea: 77 people, 77.00%
Nausea (feeling of having an urge to vomit): 49 people, 49.00%
Fatigue (feeling of tiredness): 42 people, 42.00%
Nausea And Vomiting: 30 people, 30.00%
Dehydration (dryness resulting from the removal of water): 25 people, 25.00%
Dizziness: 19 people, 19.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 18 people, 18.00%
Constipation: 18 people, 18.00%
Death: 16 people, 16.00%
Weight Decreased: 13 people, 13.00%

What are the existing conditions these people have? *

Breast Cancer: 41 people, 41.00%
Breast Cancer Female: 25 people, 25.00%
Breast Cancer Metastatic: 8 people, 8.00%
Diarrhea: 4 people, 4.00%
Nausea (feeling of having an urge to vomit): 3 people, 3.00%
Breast Neoplasm (non cancerous tumour of breast): 3 people, 3.00%
High Blood Pressure: 3 people, 3.00%
Metastases To Lung (cancer spreads to lung): 3 people, 3.00%
Metastases To Liver (cancer spreads to liver): 2 people, 2.00%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 2 people, 2.00%

* Approximation only. Some reports may have incomplete information.

Do you take Nerlynx and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nerlynx:

Nerlynx (1,946 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Nerlynx:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,641 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,611 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on neratinib maleate (the active ingredients of Nerlynx) and Nerlynx (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.